Vivimed Labs Limited

As of March 31, 2026, Vivimed Labs Limited carries a market capitalization of 436.13M, placing it among publicly traded companies globally. Its enterprise value stands at 4.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Vivimed Labs Limited has 82.91M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 0.62, and the price-to-book ratio stands at -0.21.

These figures are as of March 31, 2026. The EV/Sales ratio of 6.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.33B versus a market cap of 436.13M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Vivimed Labs Limited maintains a current ratio of 0.37, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -188.70, indicating conservative leverage, while an interest coverage ratio of -36.45 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2026. Return on assets (ROA) is negative at -21.08, reflecting losses generated across the asset base. The company generates approximately 1.19M in revenue per employee across its workforce of 586.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.06 indicates how many times Vivimed Labs Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Vivimed Labs Limited recorded 1.38M in income tax expense. The company reported a pretax loss of -1.76B and -1.76B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 21, 2026, Vivimed Labs Limited's stock has gained approximately 27.14% over the past 52 weeks. The 50-day moving average sits at 6.06, while the 200-day moving average is 6.96.

Over the twelve months ended March 31, 2026, Vivimed Labs Limited generated 699.89M in revenue and converted that into -1.76B in net income, yielding earnings per share of -21.27. EBITDA reached -1.52B, while operating income came in at -1.78B.

As of March 31, 2026, Vivimed Labs Limited holds 77.17M in cash and equivalents against 3.97B in total debt, resulting in a net debt position of 3.96B. Total book value stands at -2.11B, with working capital of -2.80B providing operational flexibility.

Over the twelve months ended March 31, 2026, Vivimed Labs Limited posted a gross margin of -5.37, reflecting its pricing power and cost economics. The operating margin of -255.03 and net profit margin of -252.14 provide insight into operational efficiency.

Vivimed Labs Limited's most recent stock split took place on April 6, 2016 with a 1:5 split ratio.